Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Novel approaches in GVHD therapy

  • J Svennilson1
  • on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation volume 35, pages S65–S67 (2005)Cite this article

Summary:

Severe graft-versus-host disease is a lethal complication to allogeneic haemopoietic stem cell transplantation. This short review gives an overview of novel treatment strategies. Psoralen-enhanced UVA irradiation (PUVA), extracorpoal PUVA, antibodies against IL-2 and TNF-alpha, thalidomide, octreotide, and mesenchymal stem cells are briefly discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  Google Scholar 

  2. Ringdén O, Hermans J, Labopin M et al, for the Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia Lymphoma 1996; 24: 71–79.

    Article  Google Scholar 

  3. Bianco JA, Higano C, Singer J et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194–1195.

    Article  CAS  Google Scholar 

  4. Ely P, Dunitz J, Rogosheske J et al. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991; 90: 707–710.

    Article  CAS  Google Scholar 

  5. Ippoliti C, Champlin R, Bugazia N et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350–3354.

    Article  CAS  Google Scholar 

  6. Wiesmann A, Weller A, Lischka G et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151–155.

    Article  CAS  Google Scholar 

  7. Greinix HT, Volc-Platzer B, Kalhs P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431.

    CAS  Google Scholar 

  8. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441.

    Article  Google Scholar 

  9. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    CAS  Google Scholar 

  10. Massenkeil G, Rackwitz S, Genvresse I et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899–903.

    Article  CAS  Google Scholar 

  11. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-alpha antibody. Bone Marrow Transplant 2001; 28: 47–49.

    Article  CAS  Google Scholar 

  12. Jacobsohn DA, Vogelsang GB . Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10: 1195–1205.

    Article  CAS  Google Scholar 

  13. Lee SJ, Zahrieh D, Agura E et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559–1564.

    Article  CAS  Google Scholar 

  14. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  Google Scholar 

  15. Kulkarni S, Powles R, Sirohi B et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32: 165–170.

    Article  CAS  Google Scholar 

  16. Arora M, Wagner JE, Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265–273.

    Article  CAS  Google Scholar 

  17. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.

    Article  Google Scholar 

  18. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389–397.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Allogeneic Stem Cell transplantation/Paediatric Haematology Unit, Huddinge University Hospital, Stockholm, Sweden

    J Svennilson

Authors
  1. J Svennilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Corresponding author

Correspondence to J Svennilson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Svennilson, J., on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Novel approaches in GVHD therapy. Bone Marrow Transplant 35 (Suppl 1), S65–S67 (2005). https://doi.org/10.1038/sj.bmt.1704850

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704850

Keywords

Search

Advanced search

Quick links